Panitumumab and irinotecan every 3 weeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancer
Identificadores
Identificadores
Fecha de publicación
2013Título de revista
Clinical & Translational Oncology
Tipo de contenido
Artigo